Tampere – Finland’s Most Desirable City to Live in – Attracts Tech Talent From Europe
10.8.2023 21:46:00 EEST | Business Wire | Press release
Nestled in the world's happiest country, Tampere, a forward-thinking city, look towards Europe for skilled tech professionals and startup entrepreneurs. Tampere’s International House is hosting an online hackathon-style recruitment event, titled Game On!, on 14–15 September. As part of the hackathon, Tampere is inviting 12 applicants to experience the true Tampere lifestyle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230810179331/en/
Tampere has a strong tech community and active ecosystems for example in machine learning, imaging, mobile and manufacturing technologies. (Photo: Business Wire)
Tampere is a city known for its courage to grow and go forward. Located in the heart of Finland, Tampere is home to blooming tech companies such as Valmet, Treon, and Colossal Order. Unlike the tech industry in many crowded cities, these tech companies can offer their employees an escape from the chaos and a lifestyle with affordable, easy-access housing and a high standard of living.
Tampere has a strong tech community and active ecosystems for example in machine learning, imaging, mobile and manufacturing technologies. The growing city and its tech industry need bright new tech minds. In the Experience Tampere campaign, European professionals are especially targeted.
Twelve of the tech professionals and startup founders who register for the event by 16 August also have a chance to win a five-day immersive experience in Tampere. There will be a versatile programme for both talents and startup owners coming to experience the hidden gem of Finland between the 12th and 16th of September.
"It will be a unique experience and an opportunity for the winners to meet the companies, get to know the city, its tech scene, and the lifestyle. Tampere will show that high tech can be combined with a vibrant community and chill sauna evenings by beautiful lakeside scenery," says Sini Vilppula, Vice President, Human Resources, at Automation System Business Line in Valmet.
For startup founders, the city organizes a programme where they get to explore the Startup Tampere ecosystem, visit co-working spaces, innovation centers, and accelerators, and feel the energy of the Platform 6 Startup House. Furthermore, connect with local startups, network with founders, gain insights from industry experts, and create new possibilities for their startups.
All participants get to experience Finnish culture with their families and discover the unique charm of Tampere, enjoy cultural activities, indulge in traditional Finnish cuisine, and build connections beyond business.
Further information:
Experience Tampere - International House Tampere
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230810179331/en/
Contact information
Marketing Specialist
Tiia Heikkilä
tiia.heikkila@tampere.fi
+358 41 730 2921
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom